Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

ENTELLECT LIMITED

ABN

41 009 221 783

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- Performance rights
- Convertible notes
- 3. Options
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 45,000,000 Performance rights (Performance Rights)
- 4 varied Convertible Notes (Notes) pursuant to a variation of existing convertible notes described below.
- 3. 100,000,000 options (**Options**)
- 3 Principal the terms of +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Performance Rights

The 45,000,000 Performance Rights are issued to a Director and a senior executive under the Company's Long Term Incentive Plan (LTIP). The Performance Rights are subject to a number of vesting conditions (revenue targets and continued directorship/employment) (Performance Hurdles) more particularly described in Entellect's Notice of 2014 AGM.

Subject to the satisfaction of the Performance Hurdles, the Director/ senior executive will

⁺ See chapter 19 for defined terms.

receive one share in the Company for each vested Performance Right. No cash consideration is payable for the issue of the Performance Rights, or on the issue of the underlying performance shares upon the vesting of the Performance Rights. The Performance Rights issued will not be listed on ASX and will not be transferable, except as permitted under the LTIP.

Convertible Notes

Pursuant to a variation of existing convertible notes as agreed upon between Entellect and the note holders, the Company advises that the terms of the varied Notes are as follows:

- a) Each Note has a face value of \$50,000;
- The Notes are unsecured, non-transferable without Entellect's consent, and will not be listed on the ASX:
- c) The Notes have a maturity date of 31 October 2015 (Maturity Date). The principal sum of the Convertible Note will be repayable upon expiry if not redeemed prior to that time;
- d) Each Note bears interest at a rate of 10% per annum on the face value of the note if such interest is paid in cash; or at 15% per annum on the face value of the note if interest is capitalised and paid out in shares. Interest will accrue and will be payable (whether in cash or shares) in arrears upon conversion or redemption.
- e) Conversion will occur at the election of the note holder at a conversion price of \$0.002;
- f) The number of shares to be issued as a result of conversion will be adjusted to reflect any bonus issues, capital returns or other reconstructions in the manner provided by the ASX Listing Rules.

Options

- a) Each Note entitles the holder to 25,000,000 free attaching options (**Options**).
- b) Each Option entitles the holder to subscribe to one fully paid ordinary share in the Company at the exercise price of \$0.002. The Options are exercisable up until 5.00pm (Melbourne time) on 31 October 2015 (Expiry Date). Any Options not exercised on or before the Expiry Date will automatically lapse.

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

The Performance Rights will not be quoted or rank equally with any class or quoted securities. However, fully paid ordinary shares issued upon exercise of the Performance rights will be quoted, and will rank equally with all other ordinary shares then on issue in the Company.

The Notes will not be quoted or rank equally with any class or quoted securities. However, fully paid ordinary shares issued on conversion of the Notes will be quoted. Under the terms of issue of the Notes, those shares will rank equally with all other ordinary shares then on issue in the Company.

The Options will not be quoted. However, shares issued on exercise of the Options will rank equally with all other ordinary shares then on issue in the Company.

5 Issue price or consideration

No consideration is payable for the issue of the Performance Rights, or on the issue of the underlying Performance Shares upon the vesting of the Performance Rights.

No consideration was payable on the varied Notes and no capital was raised by the Company in respect of the variation. The total face value of the Notes is \$200,000.

The 100,000,000 Options are issued for nil cash consideration as free attaching options to the varied Notes.

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

The Performance Rights are issued under the Company's Long Term Incentive Plan.

Prior to the variation of the Notes, the existing notes were issued to raise funds. The Company has not raised further funds through the variation of the Notes.

The Options are issued as free attaching options to the holders of the Notes.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in relation to the* *securities the subject of this Appendix 3B, and comply with section 6i

Yes

⁺ See chapter 19 for defined terms.

6b

| 6b | The date the security holder resolution under rule 7.1A was passed | 15 December 2014 |
|----|---|---|
| 6c | Number of *securities issued without security holder approval under rule 7.1 | 4 Notes (representing a maximum of 100,000,000 underlying conversion shares) 100,000,000 Options |
| 6d | Number of *securities issued with security holder approval under rule 7.1A | N/A |
| 6e | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | 20,000,000 Performance Rights are issued to a Director in accordance with shareholder approval obtained on 15 December 2014. |
| 6f | Number of *securities issued under an exception in rule 7.2 | 25,000,000 Performance Rights are issued in accordance with the Company's LTIP, for which Entellect received obtained shareholder approval on 29 November 2013. |
| 6g | If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation. | N/A |
| 6h | If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A — complete Annexure 1 and release to ASX Market Announcements | See Annexure 1 |
| 7 | *Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. | 24 December 2014 |

Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

| Number | +Class |
|---------------|----------------------------|
| 2,771,322,932 | Fully paid ordinary shares |

9 Number and *class of all *securities not quoted on ASX (*including* the *securities in section 2 if applicable)

| Number | +Class |
|-------------|--|
| 39 | Convertible Notes |
| 200,000,000 | Options exercisable at \$0.001 on or before 28 February 2015 |
| 140,100,000 | Options exercisable at \$0.002 on or before 3 October 2015 |
| 100,000,000 | Options exercisable at \$0.002 on or before 30 October 2015 |
| 134,000,000 | Performance Rights |

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Rank equally

Part 2 - Pro rata issue

| 11 | ls | security | holder | approval |
|----|-----|----------|--------|----------|
| | rec | uired? | | |

N/A

12 Is the issue renounceable or non-renounceable?

N/A

13 Ratio in which the *securities will be offered

N/A

14 *Class of *securities to which the offer relates

N/A

15 *Record date to determine entitlements

N/A

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

N/A

17 Policy for deciding entitlements in relation to fractions

N/A

⁺ See chapter 19 for defined terms.

| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents | N/A |
|----|---|-----|
| | Note: Security holders must be told how their entitlements are to be dealt with. | |
| | Cross reference: rule 7.7. | |
| 19 | Closing date for receipt of acceptances or renunciations | N/A |
| 20 | Names of any underwriters | N/A |
| | | |
| 21 | Amount of any underwriting fee or commission | N/A |
| 22 | Names of any brokers to the issue | N/A |
| | | |
| 23 | Fee or commission payable to the broker to the issue | N/A |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders | N/A |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting | N/A |
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled | N/A |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | N/A |
| 28 | Date rights trading will begin (if applicable) | N/A |
| 29 | Date rights trading will end (if applicable) | N/A |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker? | N/A |

| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | N/A |
|------------------|---|--|
| 32 | How do security holders dispose of their entitlements (except by sale through a broker)? | N/A |
| 33 | *Issue date | N/A |
| Part | t 3 - Quotation of sec | curities |
| You ne | ed only complete this section if you are | e applying for quotation of securities |
| 34 | Type of *securities (tick one) | |
| (a) | *Securities described in Pa | rt 1 ¹ |
| (b) | All other +securities | |
| | | end of the escrowed period, partly paid securities that become fully paid, when restriction ends, securities issued on expiry or conversion of |
| Entit | ies that have ticked box 3 | 34(a) |
| Addit | ional securities forming a nev | v class of securities |
| Tick to docum | indicate you are providing the informa | tion or |
| 35 | | y securities, the names of the 20 largest holders of and the number and percentage of additional olders |
| 36 | If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over | |
| 37 | A copy of any trust deed fo | r the additional +securities |
| Entit | ies that have ticked box | 34(b) |
| 38 | Number of *securities for which *quotation is sought | N/A |
| | | |

⁺ See chapter 19 for defined terms.

| 39 | *Class of *securities for which quotation is sought | N/A | |
|----|--|--------|--------|
| 40 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? | N/A | |
| | If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | | |
| 41 | Reason for request for quotation now | N/A | |
| | Example: In the case of restricted securities, end of restriction period | | |
| | (if issued upon conversion of another *security, clearly identify that other *security) | | |
| | | | |
| | | Number | +Class |
| 42 | Number and *class of all *securities quoted on ASX (including the *securities in clause 38) | N/A | N/A |
| | | | |

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any
 applications received by us in relation to any *securities to be quoted and
 that no-one has any right to return any *securities to be quoted under
 sections 737, 738 or 1016F of the Corporations Act at the time that we
 request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at the
 time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

SOPHIE KARZIS Company Secretary 24 December 2014

+ See chapter 19 for defined terms.

^{04/03/2013} Appendix 3B Page 9

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

| Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | | |
|--|--|--|--|
| | | | Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue |
| Add the following: Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval | 75,000,000 shares issued on 18 December 2013 25,000,000 shares issued on 23 December 2013 125,000,000 shares issued on 10 January 2014 100,000,000 shares issued on 11 February 2014 5,000,000 shares issued on 11 February 2014 100,000,000 shares issued on 3 March 2014 172,702,423 shares issued on 3 April 2014 59,297,577 shares issued on 3 April 2014 50,000,000 shares issued on 4 April 2014 25,000,000 shares issued on 20 May 2014 108,200,000 shares issued on 30 July 2014 | | |
| Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | N/A | | |
| Subtract the number of fully paid *ordinary securities cancelled during that 12 month period | Nil | | |
| "A" | 2,771,322,932 | | |
| Step 2: Calculate 15% of "A" | Step 2: Calculate 15% of "A" | | |
| "B" | 0.15 [Note: this value cannot be changed] | | |

| Multiply "A" by 0.15 | 415,698,439 |
|----------------------|-------------|
|----------------------|-------------|

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of *equity securities issued or agreed to be issued in that 12 month period *not counting* those issued:

- Under an exception in rule 7.2
- Under rule 7.1A
- With security holder approval under rule 7.1 or rule 7.4

Note:

- This applies to equity securities, unless specifically excluded – not just ordinary securities
- Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed
- It may be useful to set out issues of securities on different dates as separate line items

- 4 Convertible Notes issued on 24 December 2014 (which may be converted into a maximum of 100,000,000 underlying shares)
- 100,000,000 Options issued on 24 December
 2014

"C" 200,000,000

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

| "A" x 0.15 Note: number must be same as shown in Step 2 | 415,698,439 |
|---|---|
| Subtract "C" | 200,000,000 |
| Note: number must be same as shown in Step 3 | |
| <i>Total</i> ["A" x 0.15] – "C" | 215,698,439 |
| | [Note: this is the remaining placement capacity under rule 7.1] |

⁺ See chapter 19 for defined terms.

Part 2

| Rule 7.1A – Additional placement capacity for eligible entities | | |
|---|---|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | |
| "A" Note: number must be same as shown in Step 1 of Part 1 | 2,771,322,932 | |
| Step 2: Calculate 10% of "A" | | |
| "D" | 0.10 Note: this value cannot be changed | |
| Multiply "A" by 0.10 | 277,132,293 | |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used | | |
| Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items | Nil | |
| "E" | 0 | |
| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A | | |
| "A" x 0.10 | 277,132,293 | |
| Note: number must be same as shown in Step 2 | | |
| Subtract "E" | 0 | |
| Note: number must be same as shown in Step 3 | | |
| <i>Total</i> ["A" x 0.10] – "E" | 277,132,293 Note: this is the remaining placement capacity under rule 7.1A | |